RNA-seq of human NSCLC cell line treated with Tramatinib or Lorlatinib, at different time points

ABSTRACT: To better understand the differences between different ALK inhibitors on ALK positive NSCLC cell lines, we performed RNA-seq analysis on samples treated with 2 types of ALK inhibitors: Tramatinib and Lorlatinib. Samples taken 6h and 24h after treatment

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER:  

PROVIDER: E-MTAB-11834 | biostudies-arrayexpress |

SECONDARY ACCESSION(S): ERP138434

REPOSITORIES: biostudies-arrayexpress